Binary oncolytic adenovirus in combination with HER2-specific autologous CAR VST for treatment of advanced HER2-positive solid tumors (VISTA).

被引：0
|
作者：
Makawita, Shalini
Gibbs, Jerry M.
McFadden, Dustin R.
Porter, Caroline
Shaw, Amanda Rosewell
Robertson, Catherine
Woods, Mae Louise
Wang, Tao
Grilley, Bambi J.
Heslop, Helen E.
Brenner, Malcolm K.
Suzuki, Masataka
机构：
[1] Baylor Coll Med, Houston, TX USA
[2] Houston Methodist Hosp, Houston, TX USA
[3] Baylor Coll Med, Cell & Gene Therapy, Houston, TX USA
[4] Texas Childrens Hosp, Houston, TX USA
[5] Baylor Coll Med, Div Diabet Endocrinol & Metab, Houston, TX USA
[6] Baylor Coll Med, Div Pediat, Houston, TX USA
[7] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX USA
[8] Texas Childrens Hosp, Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2679
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Targeting HER2-Positive Solid Tumors with CAR NK Cells: CD44 Expression Is a Critical Modulator of HER2-Specific CAR NK Cell Efficacy
    Gergely, Bence
    Vereb, Mark A.
    Rebenku, Istvan
    Vereb, Gyorgy
    Szoor, Arpad
    CANCERS, 2025, 17 (05)
  • [2] Affitoxin-A Novel Recombinant, HER2-specific, Anticancer Agent for Targeted Therapy of HER2-positive Tumors
    Zielinski, Rafal
    Lyakhov, Ilya
    Jacobs, Amy
    Chertov, Oleg
    Kramer-Marek, Gabriela
    Francella, Nicholas
    Stephen, Andrew
    Fisher, Robert
    Blumenthal, Robert
    Capala, Jacek
    JOURNAL OF IMMUNOTHERAPY, 2009, 32 (08) : 817 - 825
  • [3] Tumor-specific oncolytic adenovirus expressing trastuzumab antibody for treatment of HER2-positive cancer
    Liikanen, I.
    Guse, K.
    Gutmann, T.
    Savola, P.
    Tahtinen, S.
    Pesonen, S. K.
    Oksanen, M.
    Kanerva, A.
    Hemminki, A.
    HUMAN GENE THERAPY, 2015, 26 (10) : A92 - A92
  • [4] AFFITOXIN - A NOVEL RECOMBINANT, HER2-SPECIFIC, ANTI-CANCER AGENT FOR TARGETED THERAPY OF HER2-POSITIVE TUMORS
    Capala, J.
    Zileinski, R.
    Lyakhov, I.
    ANNALS OF ONCOLOGY, 2010, 21 : 36 - 37
  • [5] ICG-Dimeric Her2-Specific Affibody Conjugates for Tumor Imaging and Photothermal Therapy for Her2-Positive Tumors
    Jia, Dianlong
    Liu, Huimin
    Zheng, Shuhui
    Yuan, Dandan
    Sun, Ruohan
    Wang, Fei
    Li, Yang
    Li, Hui
    Yuan, Fengjiao
    Fan, Qing
    Zhao, Zhenxiong
    MOLECULAR PHARMACEUTICS, 2023, 20 (01) : 427 - 437
  • [6] Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer
    Liikanen, Ilkka
    Tahtinen, Siri
    Guse, Kilian
    Gutmann, Theresia
    Savola, Paula
    Oksanen, Minna
    Kanerva, Anna
    Hemminki, Akseli
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (09) : 2259 - 2269
  • [7] Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial
    Hegde, Meenakshi
    Navai, Shoba
    DeRenzo, Christopher
    Joseph, Sujith K.
    Sanber, Khaled
    Wu, Mengfen
    Gad, Ahmed Z.
    Janeway, Katherine A.
    Campbell, Matthew
    Mullikin, Dolores
    Nawas, Zeid
    Robertson, Catherine
    Mathew, Pretty R.
    Zhang, Huimin
    Mehta, Birju
    Bhat, Raksha R.
    Major, Angela
    Shree, Ankita
    Gerken, Claudia
    Kalra, Mamta
    Chakraborty, Rikhia
    Thakkar, Sachin G.
    Dakhova, Olga
    Salsman, Vita S.
    Grilley, Bambi
    Lapteva, Natalia
    Gee, Adrian
    Dotti, Gianpietro
    Bao, Riyue
    Salem, Ahmed Hamed
    Wang, Tao
    Brenner, Malcolm K.
    Heslop, Helen E.
    Wels, Winfried S.
    Hicks, M. John
    Gottschalk, Stephen
    Ahmed, Nabil
    NATURE CANCER, 2024, 5 (06) : 880 - 894
  • [8] Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific affibody molecule
    Tolmachev, Vladimir
    Orlova, Anna
    Pehrson, Rikard
    Galli, Joakim
    Baastrup, Barbro
    Andersson, Karl
    Sandstrom, Mattias
    Rosik, Daniel
    Carlsson, Jorgen
    Lundqvist, Hans
    Wennborg, Anders
    Nilsson, Fredrik Y.
    CANCER RESEARCH, 2007, 67 (06) : 2773 - 2782
  • [9] Studies on the Safety and Efficacy of Pyrotinib in the Treatment of HER2-Positive Advanced Solid Tumors Excluding Breast Cancer
    Yin, Yuzhen
    Yang, Hui
    Liu, Zhuo
    Tan, Jie
    Zhu, Chunrong
    Chen, Minbin
    Zhou, Rengui
    Wane, Lei
    Qian, Jun
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 13479 - 13487
  • [10] HER2-positive advanced breast cancer treatment in 2020
    Cesca, Marcelle G.
    Vian, Lucas
    Cristovao-Ferreira, Sofia
    Ponde, Noam
    de Azambuja, Evandro
    CANCER TREATMENT REVIEWS, 2020, 88
12345